Nuo Therapeutics Inc

Nuo Therapeutics operates with a negative equity position of $956,560 and a debt-to-equity ratio of -0.52, indicating a capital structure reliant on debt and negative retained earnings. The company’s liquidity is constrained, with a current ratio of 1.06 and negative free cash flow of $2.7 million, suggesting limited capacity to meet short-term obligations without external financing. Profitability metrics reveal a gross margin of 67% (calculated as $2,217,960 gross profit / $3,313,510 revenue), which is strong for a medical device company but offset by operating losses of $2.5 million and a net loss of $2.5 million. Return on equity is 263%, but this is mathematically inflated due to negative equity. The company’s revenue is concentrated in a single product, the Aurix System, with no disclosed geographic diversification beyond the United States. This concentration increases exposure to regulatory, reimbursement, and market adoption risks. Outlook data is not provided, but historical revenue of $3.3 million suggests limited growth. The company’s operating cash flow of -$865,000 and capital expenditures of -$275,000 indicate ongoing investment in operations, though without clear revenue traction. Risk factors include medium liquidity risk due to negative net cash and low dilution risk, though the company’s equity position is negative. No dilution sources are disclosed, but the absence of diluted shares suggests no imminent pressure. Recent filings highlight the company’s focus on commercializing the Aurix System, but no material events or earnings call transcripts are disclosed in the input data.